Evidence map›Paper›PMID 37200698›Full record

ArticleRSC advances2023

Novel long-acting brimonidine tartrate loaded-PCL/PVP nanofibers for versatile biomedical applications: fabrication, characterization and antimicrobial evaluation.

Samar A Salim, Noha M Badawi, Shahira H El-Moslamy, Elbadawy A Kamoun, Baher A Daihom

Open access · goldAbstract read
In one paragraph

Article in RSC advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Samar A SalimNanotechnology Research Center (NTRC), The British University in Egypt (BUE) Cairo 11837 Egypt elbadawy.kamoun@bue.edu.eg badawykamoun@yahoo.com.
Noha M BadawiDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, The British University in Egypt (BUE) Cairo 11837 Egypt.
Shahira H El-MoslamyBioprocess Development Department (BID), Genetic Engineering and Biotechnology Research Institute (GEBRI), City of Scientific Research and Technological Applications (SRTA-City) New Borg El-Arab City Alexandria 21934 Egypt.ORCID https://orcid.org/0000-0003-0836-1444
Elbadawy A KamounPolymeric Materials Research Dep., Advanced Technology and New Materials Research Institute (ATNMRI), City of Scientific Research and Technological Applications (SRTA-City) Alexandria 21934 Egypt.ORCID https://orcid.org/0000-0002-0649-5986
Baher A DaihomDepartment of Pharmaceutics and Industrial Pharmacy, Cairo University Cairo Egypt.ORCID https://orcid.org/0000-0003-3264-3564
British University in Egypt · EGCairo University · EGCity of Scientific Research and Technological Applications · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The global state of antibiotic resistance highlights the necessity for new drugs that can treat a wide range of microbial infections. Drug repurposing has several advantages, including lower costs and improved safety compared to developing a new compound. The aim of the current study is to evaluate the repurposed antimicrobial activity of Brimonidine tartrate (BT), a well-known antiglaucoma drug, and to potentiate its antimicrobial effect by using electrospun nanofibrous scaffolds. BT-loaded nanofibers were fabricated in different drug concentrations (1.5, 3, 6, and 9%)

Identifiers

PMID37200698
PMCPMC10186146
OpenAlexW4377007992

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.